Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

ABSTRACT:

Purpose of review

Our objective is to provide a history, rationale, and review of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.

Recent findings

In the last decade, there has been an increase in the literature regarding HIPEC in the treatment of ovarian cancer. The rationale for HIPEC extends from earlier trials demonstrating improved survival using intraperitoneal chemotherapy. HIPEC provides a one-time opportunity for intraperitoneal chemotherapy at the time of cytoreduction and with the addition of hyperthermia. Cisplatin HIPEC has been demonstrated to have a survival benefit when used in the interval cytoreductive setting. In terms of safety, nephroprotection remains a key concern when administering HIPEC. Sodium thiosulf

SUBMITTER: Praiss AM 

PROVIDER: S-EPMC10091236 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature